Literature DB >> 22388097

Mesenchymal stem cells enhance GABAergic transmission in co-cultured hippocampal neurons.

Mario Mauri1, Daniela Lentini, Marta Gravati, Dana Foudah, Gerardo Biella, Barbara Costa, Mauro Toselli, Marco Parenti, Silvia Coco.   

Abstract

Bone marrow-derived mesenchymal stem cells (MSCs) are multipotent stem cells endowed with neurotrophic potential combined with immunological properties, making them a promising therapeutic tool for neurodegenerative disorders. However, the mechanisms through which MSCs promote the neurological recovery following injury or inflammation are still largely unknown, although cell replacement and paracrine mechanisms have been hypothesized. In order to find out what are the mechanisms of the trophic action of MSCs, as compared to glial cells, on CNS neurons, we set up a co-culture system where rat MSCs (or cortical astrocytes) were used as a feeding layer for hippocampal neurons without any direct contact between the two cell types. The analysis of hippocampal synaptogenesis, synaptic vesicle recycling and electrical activity show that MSCs were capable to support morphological and functional neuronal differentiation. The proliferation of hippocampal glial cells induced by the release of bioactive substance(s) from MSCs was necessary for neuronal survival. Furthermore, MSCs selectively increased hippocampal GABAergic pre-synapses. This effect was paralleled with a higher expression of the potassium/chloride KCC2 co-transporter and increased frequency and amplitude of mIPSCs and sIPSCs. The enhancement of GABA synapses was impaired by the treatment with K252a, a Trk/neurotrophin receptor blocker, and by TrkB receptor bodies hence suggesting the involvement of BDNF as a mediator of such effects. The results obtained here indicate that MSC-secreted factors induce glial-dependent neuronal survival and trigger an augmented GABAergic transmission in hippocampal cultures, highlighting a new effect by which MSCs could promote CNS repair. Our results suggest that MSCs may be useful in those neurological disorders characterized by an impairment of excitation versus inhibition balance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388097     DOI: 10.1016/j.mcn.2012.02.004

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  8 in total

1.  Administration of mesenchymal stem cells and ziprasidone enhanced amelioration of ischemic brain damage in rats.

Authors:  Phatcharida Kaengkan; Seung Eun Baek; Ji Yeong Kim; Kyung-Yoon Kam; Byung-Rok Do; Eun Shin Lee; Sung Goo Kang
Journal:  Mol Cells       Date:  2013-11-28       Impact factor: 5.034

2.  Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.

Authors:  Catarina Oliveira Miranda; Adriana Marcelo; Teresa Pereira Silva; João Barata; Ana Vasconcelos-Ferreira; Dina Pereira; Clévio Nóbrega; Sónia Duarte; Inês Barros; Joana Alves; José Sereno; Lorena Itatí Petrella; João Castelhano; Vitor Hugo Paiva; Paulo Rodrigues-Santos; Vera Alves; Isabel Nunes-Correia; Rui Jorge Nobre; Célia Gomes; Miguel Castelo-Branco; Luís Pereira de Almeida
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 3.  Evidence for high translational potential of mesenchymal stromal cell therapy to improve recovery from ischemic stroke.

Authors:  Mark A Eckert; Quynh Vu; Kate Xie; Jingxia Yu; Wenbin Liao; Steven C Cramer; Weian Zhao
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-12       Impact factor: 6.200

Review 4.  Retinitis Pigmentosa Treatment with Western Medicine and Traditional Chinese Medicine Therapies.

Authors:  Jian Xu; Qinghua Peng
Journal:  J Ophthalmol       Date:  2015-06-01       Impact factor: 1.909

Review 5.  Recent advances of stem cell therapy for retinitis pigmentosa.

Authors:  Yuxi He; Yan Zhang; Xin Liu; Emma Ghazaryan; Ying Li; Jianan Xie; Guanfang Su
Journal:  Int J Mol Sci       Date:  2014-08-20       Impact factor: 5.923

6.  Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial.

Authors:  Seyed Massood Nabavi; Leila Arab; Neda Jarooghi; Tina Bolurieh; Fatemeh Abbasi; Soura Mardpour; Vajihe Azimyian; Fatemeh Moeininia; Saman Maroufizadeh; Leila Sanjari; Seyedeh Esmat Hosseini; Nasser Aghdami
Journal:  Cell J       Date:  2018-08-01       Impact factor: 2.479

7.  A 3D in vitro model reveals differences in the astrocyte response elicited by potential stem cell therapies for CNS injury.

Authors:  Emma East; Noémie Johns; Melanie Georgiou; Jon P Golding; A Jane Loughlin; Paul J Kingham; James B Phillips
Journal:  Regen Med       Date:  2013-11       Impact factor: 3.806

8.  Comparison of the neuropoietic activity of gene-modified versus parental mesenchymal stromal cells and the identification of soluble and extracellular matrix-related neuropoietic mediators.

Authors:  Irina Aizman; Brenna J Tirumalashetty; Michael McGrogan; Casey C Case
Journal:  Stem Cell Res Ther       Date:  2014-02-26       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.